Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, USA.
Pharmacotherapy. 2012 Aug;32(8):772-80. doi: 10.1002/j.1875-9114.2012.01103.x.
To compare costs associated with a physician-pharmacist collaborative intervention with costs of usual care.
Cost analysis using health care utilization and outcome data from two prospective, cluster-randomized, controlled clinical trials.
Eleven community-based medical offices.
A total of 496 patients with hypertension; 244 were in the usual care (control) group and 252 were in the intervention group.
To compare the costs, we combined cost data from the two trials. Total costs included costs of provider time, laboratory tests, and antihypertensive drugs. Provider time was calculated based on an online survey of intervention pharmacists and the National Ambulatory Medical Care Survey. Cost parameters were taken from the Bureau of Labor Statistics for average wage rates, the Medicare laboratory fee schedule, and a publicly available Web site for drug prices. Total costs were adjusted for patient characteristics. Adjusted total costs were $774.90 in the intervention group and $445.75 in the control group (difference $329.16, p<0.001). In a sensitivity analysis, the difference in adjusted total costs between the two groups ranged from $224.27-515.56. The intervention cost required to have one additional patient achieve blood pressure control within 6 months was $1338.05, determined by the difference in costs divided by the difference in hypertension control rates between the groups ($329.16/24.6%). The cost over 6 months to lower systolic and diastolic blood pressure 1 mm Hg was $36.25 and $94.32, respectively.
The physician-pharmacist collaborative intervention increased not only blood pressure control but also the cost of care. Additional research, such as a cost-benefit or a cost-minimization analysis, is needed to assess whether financial savings related to reduced morbidity and mortality achieved from better blood pressure control outweigh the cost of the intervention.
比较医师-药剂师合作干预与常规护理相关的成本。
使用来自两项前瞻性、集群随机对照临床试验的医疗保健利用和结果数据进行成本分析。
11 个社区医疗办公室。
共 496 名高血压患者;244 名患者在常规护理(对照组),252 名患者在干预组。
为了比较成本,我们合并了两项试验的成本数据。总费用包括提供者时间、实验室检查和降压药物的成本。提供者时间是根据干预药剂师的在线调查和国家门诊医疗保健调查计算的。成本参数取自美国劳工统计局的平均工资率、医疗保险实验室费用表和一个公共可用的药品价格网站。对患者特征进行了调整。干预组的调整后总费用为 774.90 美元,对照组为 445.75 美元(差异为 329.16 美元,p<0.001)。在敏感性分析中,两组之间调整后总费用的差异范围为 224.27-515.56 美元。通过将成本差异除以两组之间高血压控制率的差异(329.16/24.6%),确定使一名额外患者在 6 个月内达到血压控制所需的干预成本为 1338.05 美元。6 个月内降低收缩压和舒张压 1mmHg 的成本分别为 36.25 美元和 94.32 美元。
医师-药剂师合作干预不仅提高了血压控制率,还增加了医疗保健成本。需要进行额外的研究,例如成本效益或成本最小化分析,以评估通过更好的血压控制实现的发病率和死亡率降低所带来的经济节省是否超过干预的成本。